Biotechnology — US PTAB Patent Cases
71 decisions indexed
Page 2 of 3 · 71 total
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN petitions the PTAB to invalidate Tecan’s ’012 patent covering nucleic‑acid enrichment for NGS, asserting that the claims are obvious over earlier academic publications. The petition argues the examiner relied on an unsupported declaration and that no secondary considerations exist.
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned to institute IPR proceedings against Tecan Genomics, challenging claims of U.S. Patent No. 10876108 based on obviousness (35 U.S.C. § 103). The Board found that the Examiner erred in relying solely on secondary considerations, adopting the Petitioner's view that combining Shapero and Delseny renders multiple claims obvious.
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully petitioned the PTAB against Tecan Genomics regarding claims related to Next-Generation Sequencing (NGS). The Board instituted review, finding a reasonable likelihood of prevailing on obviousness grounds.
QIAGEN Sciences, LLC v.Tecan Group AG
QIAGEN Sciences successfully convinced the PTAB to institute trial proceedings against Tecan Genomics, Inc. regarding a high-throughput sequencing patent (11098357). The Board found reasonable likelihood that claims 1 through 10 are unpatentable under both anticipation (§ 102) and obviousness (§ 103).
LCY Biotechnology Holding, Inc. v.Radici Chimica, S.p.A.
LCY Biotechnology and Radici Chimica have reached a settlement and jointly filed a motion to have the agreement treated as confidential and to terminate the PTAB post‑grant review. The request relies on 35 U.S.C. §327(b) and related regulations.
LCY Biotechnology Holding, Inc. v.Radici Chimica, S.p.A.
LCY Biotechnology and Radici Chimica reached a settlement, prompting a joint motion to terminate the post‑grant review of U.S. Patent 11,781,148 covering yeast metabolic engineering.
LCY Biotechnology Holding, Inc. v.Radici Chimica, S.p.A.
LCY Biotechnology has filed a PGR petition challenging Radici Chimica’s 2023 patent on engineered yeast for terpene production, arguing obviousness over Bailey and Zhang and lack of enablement due to the claim breadth.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies filed an authorized response defending the PTAB’s decision to institute an IPR against Tecan’s DNA‑sequencing patent. The petitioner argues the institution is efficient, the expert testimony is proper, and there was no abuse of discretion. The Board’s institution therefore stands.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies sought IPR of Tecan Genomics' patent covering nucleic acid technologies. The patent owner filed a terminal disclaimer of the entire patent, prompting the Board to grant an adverse judgment and terminate the proceeding.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The USPTO denied Integrated DNA Technologies’ request for Director Review of the institution decisions in three IPRs involving Tecan Genomics. The Board concluded the petitions did not merit overturning the earlier institution rulings.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB granted institution for an IPR challenging claims 1-16 of a nucleic acid analysis patent, finding reasonable likelihood of success. The Board rejected the Patent Owner's motion to deny based on prior art similarity, allowing the technical merits of anticipation and obviousness over Kivioja and Bielas to proceed to trial.
Illumina, Inc. v.Molecular Loop Biosciences, Inc.
The PTAB upheld the patentability of claims 1-9 for Molecular Loop Biosciences against Illumina. The Board rejected all grounds of anticipation and obviousness over prior art like Chee, finding that the required 'collapsing step' necessitates combining both target sequence and differentiator tag information.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
Carl Batt, an expert for Lawrence Livermore, submits a declaration defending the RE43,365 patent against Bio‑Rad’s IPR. He contends that the cited prior art (Ismagilov, Quake, Holliger, SchneegaB, etc.) does not anticipate or render the claims obvious. The Board has already instituted the proceeding.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
Bio‑Rad has filed an IPR petition challenging Caltech’s ’921 patent covering multiplex PCR assays, asserting that the claims are fully anticipated or obvious over prior art such as Larson, Saxonov, and Silverbrook.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
Bio-Rad Laboratories successfully secured the institution of its IPR against California Institute of Technology's patent, challenging claims based on anticipation and obviousness. The Board found that Bio-Rad demonstrated a reasonable likelihood of prevailing regarding Claim 1 over Larson.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
The PTAB issued a Final Written Decision rejecting all claims (1-19) of the '921 patent. The Board rejected arguments based on obviousness and novelty, particularly concerning multi-occupancy droplet detection in multiplexed biochemical assays.
Alamar Biosciences, Inc. v.Olink Proteomics AB et al.
Alamar Biosciences petitions the PTAB to invalidate claims 1‑20 of Olink's 7,883,848 patent, arguing they are obvious over prior art combinations such as Kanan/Neri and Baez/Landegren. The petitioner asserts the examiner omitted critical references and that no discretionary factors justify denial.
Alamar Biosciences, Inc. v.Olink Proteomics AB et al.
The petitioner failed to prove the obviousness of claims 1-20 of U.S. Patent No. 7883848 in a Final Written Decision. The Board adopted a specific claim construction for 'selecting all cis-reactive cells exhibiting the detectable trace,' defining it as selecting associations of at least two interactor moieties joined by an associated oligonucleotide that exhibit the detectable trace.
Ecto World, LLC d/b/a Demand Vape et al. v.RAI Strategic Holdings, Inc. et al.
The Director granted review in an IPR case (IPR2024-01280), vacating the denial of institution. The proceeding is remanded for parties to clarify arguments regarding discretionary denial under 35 U.S.C. § 325(d) and parallel ITC litigation.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
Bio-Rad Laboratories has filed an IPR challenging the validity of a patent covering multiplex digital PCR assays owned by California Institute of Technology et al. The petitioner argues that the claimed methods are unpatentably obvious, representing only a straightforward extension of existing nucleic acid analysis concepts.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
Bio-Rad Laboratories filed a Petition challenging the obviousness of nine claims in patent 10068051, which relates to molecular diagnostics/PCR methods. The petitioner argues that the claimed multiplexed detection techniques are straightforward extensions of existing prior art concepts found in references like Saxonov and Silverbrook.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
The PTAB denied Bio-Rad Laboratories' request for rehearing regarding the denial of institution in IPR2024-01178, upholding its finding that the petitioner failed to meet the burden of proving unpatentability.
PreOmics GmbH et al. v.The Brigham and Women’s Hospital, Inc.
PreOmics and Biognosys have filed an IPR petition challenging 11 claims of the ’360 patent, asserting that the nanoparticle‑based protein assay is fully anticipated or obvious over prior publications by Hu, Cai, and Zaccaria.
PreOmics GmbH et al. v.The Brigham and Women’s Hospital, Inc.
The Board found that six claims (1, 4, 6, 17, 22, and 25) of the patent were unpatentable based on anticipation by prior art Cai. The decision hinged on a broad interpretation of key terms like 'biological sample' and 'subset of particles,' which favored the Petitioner's arguments regarding the scope of the claims.
NeoGenomics Laboratories, Inc. v.Natera, Inc.
NeoGenomics filed an IPR challenging Natera's prenatal‑testing patent. The parties settled before the Board could institute the trial, and the Board granted a joint motion to terminate the proceeding.
NeoGenomics Laboratories, Inc. v.Natera, Inc.
NeoGenomics and Natera have filed a joint motion to keep their settlement agreement confidential under 35 U.S.C. § 317(b). The request seeks limited disclosure and asserts no filing fee is due.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Tecan Group AG petitions the PTAB Director to overturn the institution of an IPR filed by Integrated DNA Technologies, arguing the Panel misapplied expert testimony and misread the Meyer prior art. The request also cites policy concerns over multiple overlapping petitions.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
The PTAB denied Integrated DNA Technologies' request for Director Review of the institution decisions in two IPRs involving Tecan Group's patents, leaving the institution rulings in place.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies filed an authorized response to the PTAB Director’s review request, defending the institution of an IPR against its DNA‑sequencing patents. The petitioner argues the Board acted within policy, relied properly on the Meyer reference, and did not abuse discretion.
Integrated DNA Technologies, Inc. et al. v.Tecan Group AG
Integrated DNA Technologies successfully challenged the '108 patent's claims in a PTAB institution decision, finding reasonable likelihood of prevailing on anticipation for Claim 1. The Board affirmed that prior art disclosure was sufficient to support the enrichment limitation using Meyer et al.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.